RECURSION PHARMACEUTICALS INC - COMMON STOCK (DNA)

CUSIP: 37611X100

Q4 2021 13F Holders as of 31 Dec 2021

Holder snapshot 7 signals
Share change
+106,851,363
Put/Call ratio
81%
SEC-reported price per share
$8.31
Number of holders
158
Value change
+$844,855,283
Number of buys
100
Open additional details 1 more signal available
Number of sells
61
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
518,011,600

Security key

37611X100

Report period

Q4 2021

Institutions

158

Top holders

10

Ownership snapshot

Top reported holders of DNA - RECURSION PHARMACEUTICALS INC - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Lux Ventures IV, L.P.
Disclosed value leader
VIKING GLOBAL INVESTORS LP
Comparable rows
0/15
Latest evidence
07 Dec 2021
3/4/5 13F Highest disclosed value: $3,929,649,000 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

VIKING GLOBAL INVESTORS LP has the largest disclosed position value at $3.93B.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens VIKING GLOBAL INVESTORS LP's linked filing trail.
Disclosed position value Top 5
Lux Ventures IV, L.P. $137.71M
MIC Capital Partners (Public) Par... $14.69M
VIKING GLOBAL INVESTORS LP $3.93B
BAILLIE GIFFORD & CO $1.56B
GENERAL ATLANTIC, L.P. $1.33B

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Lux Ventures IV, L.P.
3/4/5
Former 10% Owner
—
denominator unverified
$137,710,376
13,021,519 shares
— 07 Dec 2021
MIC Capital Partners (Public) Parallel Cayman, LP
3/4/5
10%+ Owner
—
denominator unverified
$14,688,335
1,388,889 shares
— 01 Nov 2021
VIKING GLOBAL INVESTORS LP
13F
Company
13F
—
denominator unverified
$3,929,649,000
339,055,144 shares
— 30 Sep 2021
BAILLIE GIFFORD & CO
13F
Company
13F
—
mixed-class rows
$1,562,354,000
113,064,184 shares
mixed-class rows
— 30 Sep 2021
GENERAL ATLANTIC, L.P.
13F
Company
13F
—
denominator unverified
$1,331,539,000
114,886,852 shares
— 30 Sep 2021
Senator Investment Group LP
13F
Company
13F
—
denominator unverified
$912,171,000
78,703,273 shares
— 30 Sep 2021
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2021

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
158
Shares
896,807,871
Rows available
158
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2021 vs Q2 2026 Across Filers

Q2 2026 holders
1
Q4 2021 holders
158
Holder diff
157
Investor Q2 2026 Shares Q4 2021 Shares Share Diff Share Chg % Q2 2026 value Q4 2021 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .